Elad Sandbank

Elad Sandbank

Auto-generated profile, based on publicly available information

Elad Sandbank

School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2021 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
AEAnabel Eckerling
Anabel Eckerling
IRItay Ricon-Becker
Itay Ricon-Becker
LSLiat Sorski
Liat Sorski
ESElad Sandbank
Elad Sandbank
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu

7 August 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ESElad Sandbank
Elad Sandbank
AEAnabel Eckerling
Anabel Eckerling
AMAdam Margalit
Adam Margalit
LSLiat Sorski
Liat Sorski
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu
Tumor excision is a necessary life-saving procedure in most solid cancers. However, surgery and the days before and following it, known as the immediate perioperative period (IPP), entail numerous prometastatic processes, including the suppression of antimetastatic immunity and direct stimulation of minimal residual disease (MRD). Thus, the IPP is pivotal in determining long-term cancer outcomes, presenting a short window of opportunity to circumvent perioperative risk factors by employing several therapeutic approaches, including immunotherapy. Nevertheless, immunotherapy is rarely examined or implemented during this short timeframe, due to both established and hypothetical contraindications to surgery. Herein, we analyze how various aspects of the IPP promote immunosuppression and progression of MRD, and how potential IPP application of immunotherapy may interact with these deleterious processes. We discuss the feasibility and safety of different immunotherapies during the IPP with a focus on the latest approaches of immune checkpoint inhibition. Last, we address the few past and ongoing clinical trials that exploit the IPP timeframe for anticancer immunotherapy. Accordingly, we suggest that several specific immunotherapies can be safely and successfully applied during the IPP, alone or with supporting interventions, which may improve patients’ resistance to MRD and overall survival.

14 August 2024 in International Journal of Surgery
Verified
Journal Article
Open access
ESElad Msc Sandbank
Elad Msc Sandbank
PMPini Matzner
Pini Matzner
AEAnabel Eckerling
Anabel Eckerling
LSLiat Sorski
Liat Sorski
ERElla Rossene
Ella Rossene
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu
Background: The perioperative period often involves stress responses and surgery-induced hypothermia, which were suggested to hinder antimetastatic immunity and promote cancer metastasis. During this critical period, immunotherapies are rarely used, given contraindications to surgery. However, recent preclinical studies support the feasibility of perioperative TLR-9 activation using CpG-C. Materials and methods: Herein, we employed hypothermic-stress and normothermic-stress paradigms to assess their impact on perioperative CpG-C immune stimulation and resistance to experimental hepatic metastasis of CT26 colorectal cancer in BALB/c mice. Results: Perioperative hypothermic wet-cage stress markedly abrogated CpG-C-induced increase in plasma IL-12 levels, a persistent deleterious effect across different CpG-C doses and administration routes. These effects were not attenuated by blocking glucocorticoids, adrenergic, or opioid signaling, nor by adrenalectomy, suggesting a direct immunosuppressive impact of hypothermia on immunocytes. Indeed, normothermic wet-cage stress, which induced a similar corticosterone response, caused significantly less deleterious effects on IL-12 levels, hepatic NK cell maturation and cytotoxicity, and CT26 metastasis. Additionally, in-vitro exposure of PBMCs to 33°C markedly decreased CpG-C-induced IL-12 production. Last, two normothermic stress paradigms, tilt&light and restraint, did not jeopardize CpG-C-induced IL-12 response nor resistance to CT26 metastases. Interestingly, attenuating glucocorticoid signaling under tilt&light conditions improved CpG-C efficacy. Conclusions: Overall, these findings suggest that perioperative hypothermic stress can jeopardize antimetastatic immunity and resistance to metastasis, and prevent perioperative response to immune stimulation and its beneficial antimetastatic impacts, effects that are not mediated through classical neuroendocrine stress responses, but potentially through direct hypothermic impact on leukocytes. These findings may have clinical implications in operated cancer patients, many of whom suffer hypothermic stress.

23 May 2025 in Neoplasia
Verified
Journal Article
Open access
YAYosi Azan
Yosi Azan
AMAdam Margalit
Adam Margalit
GWGal Wiener
Gal Wiener
ESElad Sandbank
Elad Sandbank
RDRavid Doron
Ravid Doron
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu
Cancer patients are often treated perioperatively with serotonin reuptake inhibitors (SSRIs) to counteract anxiety and depression. Recent studies suggest that long-term cancer outcomes may also be affected by SSRI use in an agent-dependent manner. Importantly, the perioperative use of SSRIs is prevalent clinically, but has rarely been studied empirically. Herein, we studied escitalopram, a commonly prescribed SSRI in cancer patients, in vitro, and in vivo in the context of surgery and/or cancer progression in immune-competent rodents, employing the Panc02 (pancreatic), MADB106, 4T1, EO771 (mammary), and CT26 (colon) syngeneic tumor models, assessing primary tumor growth and metastasis. Escitalopram (10-15mg/kg/day, 14-30 days) was administered along tumor and/or metastatic progression, via intraperitoneal injections, Alzet osmotic pumps, or drinking water. In vitro, escitalopram affected proliferation rates in a cell-line-, dose-, and exposure duration- dependent manner, mostly increasing or not affecting proliferation. In contrast, in vivo escitalopram consistently increased primary tumor growth, and experimental and spontaneous metastasis in all models tested. In pancreatic tumor-bearing mice, escitalopram increased tumor growth in two different studies by ∼1.5-fold, as indicated by bioluminescence imaging. In the mammary primary tumor models, escitalopram increased 4T1 and EO771 growth by 1.4 to 2.2-fold. Last, escitalopram increased experimental MADB106 lung metastasis and CT26 liver metastasis, as well as spontaneous post-excision 4T1 lung metastasis by 1.6 to 2.3-fold. Taken together, although additional research is needed to elucidate mediating in vivo mechanisms, and to assess clinical oncological risks of escitalopram, these findings raise concerns regarding the prevalent perioperative use of escitalopram in cancer patients.


21 November 2022 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
AEAnabel Eckerling
Anabel Eckerling
ESElad Sandbank
Elad Sandbank
NFNadav Fogel
Nadav Fogel
NSNahida Sakis
Nahida Sakis
RHRita Haldar
Rita Haldar
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu